Eladocagene exuparvovec-tneq

Brand names: Kebilidi · Active ingredient: Eladocagene Exuparvovec

In short: KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under accelerated approval based on the change from

Forms & strengthsKEBILIDI is a sterile suspension for intraputaminal infusion. Each single-dose vial contains 2.8×1011 vg/0.5 mL (nominal concentration of 5.6×1011 vg/mL) of KEBILIDI and each 2 mL vial contains an extractable volume of 0.5 mL. …
LabelPTC Therapeutics, Inc.
Label updatedJun 18, 2026

What is Eladocagene exuparvovec-tneq used for?

KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.

This indication is approved under accelerated approval based on the change from baseline in gross motor milestone achievement at 48 weeks post treatment . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Eladocagene exuparvovec-tneq dosage

For single-dose intraputaminal infusion only.

Confirm patient has AADC deficiency due to biallelic mutations in the DDC gene.

Strictly observe aseptic technique during preparation and administration of KEBILIDI.

KEBILIDI should be administered in a medical center which specializes in stereotactic neurosurgery.

Administer KEBILIDI only using an FDA-authorized cannula for intraparenchymal infusion (i.e., ClearPoint SmartFlow Neuro Cannula Part Number NGS-NC-01-EE or NGS-NC-02-EE).

Use of the syringe (i.e., connecting the syringe to the syringe pump and priming of the cannula) should begin within 6 hours of starting product thaw

KEBILIDI is intended to be administered with an infusion pump capable of infusing at a rate of 0.003 mL/min.

KEBILIDI is administered as four intraputaminal infusions in a single stereotactic neurosurgical procedure as per the recommended dose shown in Table 1.

Table 1: Recommended Dose of KEBILIDI

Total Recommended Dose | 1.8x1011 vg (0.32 mL)

Total number of infusions | 4

Volume (dose) per infusion | 0.08 mL (0.45x1011 vg)

Location of infusions | 2 in anterior putamen, 2 in posterior putamen

Infusion rate at each target point | 0.003 mL/min

Dose duration for infusion at each target point | 27 minutes

Thawing KEBILIDI Vial

Coordinate timing of KEBILIDI thaw and infusion. KEBILIDI should be used within 6 hours of starting product thaw. Infusion of KEBILIDI takes 4 hours. The maximum time from thaw to completion of infusion should be no more than 10 hours.

Thaw the KEBILIDI vial upright at room temperature before use. The contents of the vial will thaw in approximately 15 minutes at room temperature. Do not thaw or warm the vial any other way. Gently invert the vial 3 times. Do not shake the vial.

Inspect the fully thawed KEBILIDI vial after mixing. KEBILIDI should be inspected visually for particulate matter, and discoloration prior to administration. KEBILIDI is clear to slightly opaque. The color of KEBILIDI should be a colorless to faint white suspension

Do not use if particulates, or discoloration are visible in the suspension. …

How to take Eladocagene exuparvovec-tneq — instructions & advice from the label

Discuss the following with patients and caregivers:

Administration: Inform patients/caregivers that KEBILIDI administration involves an infusion into the brain that is administered during the neurosurgical procedure .

Procedural Complications: Inform patients/caregivers about the complications of the neurosurgical procedure required for administration of KEBILIDI, including respiratory and cardiac arrest, cerebrospinal fluid (CSF) leak, intracranial bleeding, neuroinflammation, acute infarction, and infection .

Dyskinesia: Inform patients/caregivers that they may experience dyskinesia within 3 months after treatment with KEBILIDI. Symptoms of dyskinesia may include involuntary movements of face, arm, leg, or entire body which may present as fidgeting, writhing, wriggling, head bobbing or body swaying. Advise patients and caregivers to contact their healthcare provider if these symptoms occur .

Vector Shedding: Inform patients/caregivers that temporary vector shedding of KEBILIDI may occur for 3 weeks after administration. …

Warnings & precautions

Do not take this medicine if: KEBILIDI is contraindicated in patients who have not achieved skull maturity assessed by neuroimaging. Skull maturity is needed for stereotactic neurosurgical administration of KEBILIDI.

Procedural complications have been reported after neurosurgery required for KEBILIDI administration. These events included respiratory and cardiac arrest which occurred within 24 hours of the neurosurgical procedure and during post-surgical care . KEBILIDI administration has the potential risk for additional procedure related adverse events including cerebrospinal fluid (CSF) leak, intracranial bleeding, neuroinflammation, acute infarction, and infection.

Monitor patients for procedure related adverse events with KEBILIDI administration, including continuous cardiorespiratory monitoring during hospitalization.

Dyskinesia was reported after administration of KEBILIDI. All events were reported within 3 months of administration and 2 events required hospitalization .

Monitor patients for signs and symptoms of dyskinesia after KEBILIDI treatment which may include involuntary movements of face, arm, leg, or entire body. These may present as fidgeting, writhing, wriggling, head bobbing or body swaying. The use of dopamine antagonists may be considered to control dyskinesia symptoms.

Eladocagene exuparvovec-tneq side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described in this section reflects exposure to KEBILIDI in 13 pediatric patients with genetically confirmed AADC deficiency who received a single dose of 1.8×1011 vg. The median duration of follow-up was 72 weeks (range 23 to 109 weeks) .

The most common adverse reactions (incidence ≥15%) are summarized in Table 3.

Table 3: Adverse Reactions in ≥15% of Patients in Study 1

*Procedural complications included respiratory and cardiac arrest.

Adverse Reaction | Patients Treated with KEBILIDIN=13 (%)

Dyskinesia | 10 (77%)

Pyrexia | 5 (38%)

Hypotension | 4 (31%)

Anemia | 4 (31%)

Salivary hypersecretion | 3 (23%)

Hypokalemia | 3 (23%)

Hypophosphatemia | 3 (23%)

Insomnia | 3 (23%)

Hypomagnesemia | 2 (15%)

Procedural complications* | 2 (15%)

Other clinically significant adverse reaction includes worsening in duration and frequency of oculogyric crises during hospitalization following administration of KEBILIDI reported in one patient.

About this medicine

KEBILIDI (eladocagene exuparvovec-tneq) is a gene therapy product that expresses the human aromatic L-amino acid decarboxylase enzyme (hAADC). It is a recombinant adeno-associated virus serotype 2 (rAAV2) based vector containing the complementary DNA of the human DDC gene under the control of the cytomegalovirus immediate-early promoter. Eladocagene exuparvovec-tneq is produced in human embryonic kidney cells by recombinant DNA technology.

KEBILIDI is a sterile suspension administered by bilateral intraputaminal infusion in one surgical session at two sites (anterior and posterior) per putamen. Each single-dose 2 mL vial contains 2.8×1011 vg in an extractable volume of 0.5 mL of suspension. Each mL of suspension contains 5.6×1011 vg. Patients will receive a total dose of 1.8×1011 vg delivered as four 0.08 mL (0.45×1011 vg) infusions (two per putamen).

KEBILIDI is provided in a single-dose 2 mL vial containing a clear to slightly opaque, colorless to faint white liquid, free of visible particulates following thaw from its frozen state. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9d6a6401-c6b5-4f29-af11-67707d249482. Read the full official label on DailyMed.